赤天化(600227) - 2019 Q1 - 季度财报

Financial Performance - Operating revenue for the period was CNY 423,395,865.84, representing a decline of 18.32% year-on-year[6] - Net profit attributable to shareholders of the listed company was a loss of CNY 32,024,364.62, a decrease of 172.51% compared to the same period last year[6] - Basic earnings per share were CNY -0.0189, a decrease of 174.41% compared to the previous year[6] - Operating profit decreased by 153.72% year-on-year to -¥28,703,888.79, impacted by low methanol prices and reduced pharmaceutical sales[15] - The company reported a net loss for the quarter, reflecting challenges in revenue generation and cost management[25] - The net profit for Q1 2019 was a loss of CNY 32,407,099.13, compared to a profit of CNY 44,163,453.71 in Q1 2018, indicating a significant decline[28] - The total comprehensive income for Q1 2019 was a loss of CNY 32,407,099.13, compared to a profit of CNY 44,163,453.71 in Q1 2018[27] - The company's operating profit margin has significantly decreased, reflecting challenges in maintaining profitability[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,656,570,830.28, a decrease of 0.19% compared to the end of the previous year[6] - Total liabilities were CNY 549,601,001.76, an increase of 2.4% from CNY 534,344,643.76 in the previous period[24] - Total assets amounted to CNY 6,668,953,203.82, with current assets at CNY 1,765,647,528.05 and non-current assets at CNY 4,903,305,675.77[39] - Current liabilities totaled CNY 1,561,061,018.04, including short-term borrowings of CNY 252,450,000.00 and accounts payable of CNY 353,221,189.95[39] - Non-current liabilities were CNY 245,855,980.98, with long-term borrowings at CNY 174,971,787.04[39] - Total liabilities were reported at $534.34 million, with current liabilities totaling $534.34 million and non-current liabilities not specified[44] Shareholder Information - Net assets attributable to shareholders of the listed company were CNY 4,829,340,958.36, down 0.66% from the previous year[6] - The total number of shareholders at the end of the reporting period was 80,344[10] - The top ten shareholders held a total of 447,733,356 shares, accounting for 26.44% of the total shares[10] - Shareholders' equity reached approximately $5.76 billion, including paid-in capital of $1.69 billion and retained earnings of $903.32 million[44] Cash Flow - The net cash flow from operating activities was CNY 32,689,673.59, an increase of 36.32% year-on-year[6] - Net cash flow from operating activities increased by 36.32% year-on-year to ¥32,689,673.59, due to higher cash receipts from sales[15] - The net cash flow from investing activities was ¥96,728,643.08, significantly improved from -¥43,729,458.48 in the previous period[15] - The net cash flow from financing activities was -¥126,747,856.01, worsening from -¥109,118,138.86 in Q1 2018, reflecting increased cash outflows for debt repayment and other financing activities[32] - The total cash inflow from investment activities was ¥109,608,888.89, significantly higher than ¥10,000,000.00 in the previous year, indicating a strong investment recovery[32] Expenses - Tax and additional fees decreased by 41.06% year-on-year to ¥2,377,715.00 due to a decline in sales revenue[15] - Sales expenses decreased by 25.56% year-on-year to ¥41,072,223.13, reflecting reduced sales activity[15] - R&D expenses increased by 43.85% year-on-year to ¥6,804,360.69, driven by higher investment in subsidiary research[15] - The company's financial expenses for Q1 2019 were CNY 1,030,546.85, a decrease from CNY 3,603,881.27 in Q1 2018[27] Future Outlook - Future outlook includes a focus on expanding product lines and enhancing market presence through strategic initiatives[25] - The company is focusing on improving operational efficiency and reducing financial costs to enhance future profitability[28] Inventory and Receivables Management - The report indicates a significant focus on managing receivables and inventory levels to optimize cash flow[38] - Accounts receivable decreased to CNY 88,800,918.95 from CNY 179,377,041.25, indicating a significant reduction in outstanding receivables[22] - Inventory was valued at CNY 247,092,772.38, contributing to the total current assets[38]